Articles On Hera Med (ASX:HMD)

Small caps and benchmark down over 1% All sectors retreat on ill-winds blowing in from the states Tinkler is back   The ASX 200 has started a new week with its worst session since early July. While that can be pinned on a shift in US sent...

Pregnancy technology company HeraMED (HMD) enters a trading halt as the company prepares to undertake a capital raise Trading of HMD shares will be paused until Wednesday, August 24, or until the company releases further details HMD’s Hera...

HeraMed signs US deal worth $500k Pregnancy medtech specialist, HeraMed (ASX:HMD), was up over 20% this morning after revealing a supply deal with US-based e-Lōvu Health. The expected revenue to HeraMED from the deal is approximately US$550...

HeraMED (HMD) partners with e-Lōvu Health to supply its HeraCARE remote pregnancy monitoring technology to customers in the United States The companies strike a binding term sheet that will see the HeraMED supply 1000 kits to expectant mot...

ASX is set to open higher on Thursday The US Fed raises key rate by 75bp Fed Chair Powell says the US economy is not in a recession Local shares are set to rise on Thursday and at 8am AEST, the ASX 200 August futures is pointing up by 0.9...

Pregnancy technology company HeraMED (HMD) completes the HeraBEAT clinical trial with Israel’s Sheba Medical Center which achieved “excellent” results A total of 10 patients were recruited in the study and went through an observation telem...

Benchmark down, small caps up Utilities ahead 1% and well, the energy sector is on fire And why early buyer James Gerrish from Market Matters was never bearish on WHC  The ASX Emerging Companies (XEC) index has closed 0.6% higher and the...

HeraMED’s device is effective for telemedicine in monitoring pregnant women Mesoblast issues strong study results OncoSil announces success in Spain Just-released results from a clinical trial undertaken by Israel’s Sheba Medical Center c...

Stockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

 Highlights Virtual OB paid pilot of HeraMED in partnership with Pediatrix® Medical Group receives excellent satisfaction from patients and encouraging results HeraBEAT enables pregnant mothers to listen to their baby’s heartbeat anyti...

ASX health stocks (XHJ index) are down .99% today but faring better than the ASX 200 which has fallen sharply at 1.5%. The HeraMED (ASX:HMD) share price rallied 6.9% to 31 cents in early morning trade before settling ~3.45% as the company a...

Digital maternity care company HeraMED (HMD) has hit a “truly significant milestone” with a Perth hospital, The Joondalup Health Campus (JHC) JHC has agreed to use the HeraCARE solutions as its primary standard of care for expected mothers...

The ASX 200 posted a small 0.11 fall on Tuesday, outperformed by the small end of town as the microcap Emerging Companies index rose by 0.66%. There were no clear catalysts as Asian markets struggled for direction after Wall Street was clos...

Medical tech company HeraMED (HMD) raises roughly $2.39 million through a convertible note placement The placement was strongly supported by institutional and sophisticated investors The proceeds will fast-track the commercial roll out of...

It’s been a busy morning for the ASX Healthcare sector, with plenty of positive announcements for investors to digest. But the Health Index (XHJ) is trading down by 0.5% at the time of writing, compared to the broader index which is trading...

It’s been a mixed week for the ASX but it has finished on a high. The ASX 200 closed 0.69% higher than yesterday, closing at 7,362 which marked a 3 week high but is still 3.5% above the all time high reached in mid-August. Travel stocks gai...

Local stocks posted a strong session on Thursday, as the ASX 200 climbed by around 1% while the microcap Emerging Markets index jumped again (+1.9%). Asian markets were buoyant more broadly, following a steady session on Wall Street overnig...

Pregnancy technology company HeraMED (HMD) enters a trading halt while it considers, plans and executes a capital raising The company will remain in the halt until October 18 or when an announcement is made released, whichever occurs firs...

“Your Stock Request” is a weekly video where we analyse share price charts for stocks on the Australian market (ASX) as requested by you! Email us at [email protected] with your stock request. Limit of one per person, no guarantee o...

Highlights Biotechnology firm Mesoblast extended its loss on disappointing earnings and dropped 5%. Graphite producer Volt Resources dropped despite successfully raising capital via share placement. Medical data and technology firm He...

Highlights The ASX 200 declined as much as 1% by lunchtime as investors awaited June quarter GDP figures. Australia’s Q2 GDP rose 0.7% in the June quarter. Barring energy, all indices were trading in the red, while healthcare declined...

ShareCafeHidden Gems Webinar Recap – EXL, WOA, OSX & HMD Catch up on the full webinar with presentations from  Elixinol Wellness (ASX: EXL), Wide Open Agriculture (ASX: WOA), Osteopore (ASX: OSX)  & HeraMED (ASX: HMD). Hidden Gems...

“Your Stock Request” is a weekly video where we analyse share price charts for stocks on the Australian market (ASX) as requested by you! Email us at [email protected] with your stock request. Limit of one per person, no guarantee o...

Summary Advanced Human Imaging has entered into a binding agreement with Jana Care to bring affordable digitally connected care to everyone. PainChek Infant has obtained the necessary regulatory approvals in multiple International mark...

The HeraMED Ltd (ASX: HMD) share price tanked today, closing 9% lower at 15 cents apiece. This came despite the company signed a pilot deal with Obstetrix Medical, one of the USA’s largest women’s and children’s healthcare providers. HeraM...

While there appeared to be several winners out of Budget 2021, few of them were on the ASX. The ASX 200 fell for the second day in a row losing 0.73 per cent to close at 7,045 points. Meanwhile the ASX Emerging Companies Index fell 0.51 per...

After closing at a record high yesterday the ASX retreated by nearly 1 per cent today. The ASX 200 lost 1.06 per cent to close at 7,097 points. The ASX Emerging Companies Index fared worse closing 2.3 per cent in the red – at 2,060 points....

Google April 2021 and the first things you’ll find isn’t ASX winners but questions about COVID-19. Just another month in the pandemic, right? Well, yes and no. On one hand the vaccine race continues across the world – far slower than we’d l...

Summary With the current emergency, it is anticipated that telehealth or telemedicine could be the future of medicine. COVID-19 pandemic resulted in considerable adoption of telehealth solutions, mainly to avoid physical contact. The...

HeraMED has announced a paid pilot with a leading medical provider for 100 expectant mothers. HeraMED’s (ASX:HMD) HeraCARE platform will be rolled out to 100 expectant mothers at WA’s Joondalup Health Campus as part of a landmark paid pilo...

The ASX fell again today, as risk-on sentiment continued to reign supreme in the markets. The ASX 200 fell 0.29 per cent, a smaller drop then yesterday but one that saw it close below 7,000 – at 6,997. Small caps fell by more, with the ASX...

The ASX 200 has finished the day in the red but is still above 7,000 points. The ASX 200 shed 0.68 per cent closing at 7,018 points while the ASX Emerging Companied Index fell 0.33 per cent, closing at 2,101 points. All sectors were in the...

The official publication of the American College of Obstetricians and Gynecologists has endorsed the results of a clinical trial into HeraMED’s foetal monitoring device. HeraMED (ASX:HMD) is a step closer to commercialisation following the...

Source:New Africa ,Shutterstock Summary COVID-19 had a significant impact on the HeraMED’s and Adherium’s first half 2021 results. However, the two players made critical developments during the period. HeraMED plans to expand further...

Summary With COVID-19 giving the opportunity to develop products, enhance services and conduct R&D, healthcare sector will be vigilantly gauged. Early spotting of a winning penny stock can offer considerable rewards to patient and...

Summary Amid growing adoption of digital platforms, Global Health registered a robust half-year performance. Total customer revenue for the period was up by 20% on PCP. The MasterCare platform for community health care providers exper...

Summary Global Health Ltd (ASX:GLH) said Lifecard Patient Portal is seeing high demand as health delivery organisations have embraced digital engagement with patients. Lifecard Patient Portal assists consumers and doctors in managing d...

Summary HeraMED’s partnership with eCare21 aims to fast-track awareness of HeraCARE and HeraBEAT across the US. Dimerix drug compound DMX-200 is set to be tested for COVID-19-induced ARDS in the global study. Dimerix is confident that...

Maternity-focused technology start-up HeraMED (ASX: HMD) has signed an agreement with US virtual care provider eCare21 to integrate its smart pregnancy monitoring solutions into eCare21’s software-as-a-service (SaaS) platform. Under the agr...

ASX telehealth stocks have had a solid six months, gaining 25 per cent, but there are warnings more has to be done to maintain the run. The breakout of COVID-19 resulted in wide-spread adoption of telehealth as medical professionals were fo...

Telehealth use has only continued to increase as COVID-19 wore on throughout May and June. Both listed and non-listed plays such as healthcare booking service HealthEngine saw demand rise exponentially as the pandemic broke out and this has...

Special Report: Maternity health digitiser HeraMED has raised serious cash from new and existing sophisticated and institutional investors to speed the rollout of its software platform HeraCARE. HeraMED (ASX:HMD) has raised $2.32m to speed...

Special Report: Maternal health tech company HeraMED is preparing for clinical trials in Australia with a new partnership. HeraMED (ASX:HMD) is getting ready to run clinical trials for its maternity care telehealth and remote monitoring so...

Special Report: Medical tech company HeraMED has signed an exclusive deal to distribute its foetal heart rate monitors in Australia. HeraMED (ASX:HMD) is accelerating its commercialisation strategy with an exclusive two-year Australian dist...

As we approach the middle of 2020, the investment environment surrounding the fallout from the COVID-19 pandemic remains complex. Along with threats, there will be plenty of opportunities. And it’s against that backdrop that this week marke...

VidCon is Stockhead’s new virtual conference series, bringing you expert insights, panel discussions and presentations on the most interesting and relevant investment sectors from leading analysts, listed small caps and industry participant...

Seasoned financial advisor, investment manager and corporate director Dr Nigel Finch is back in the radio booth for another instalment of The StockDoc Podcast. In this episode the good doctor sits down with Alexander Radke, general manager...

Stock Talk is a new Stockhead video series featuring a roundtable of experts discussing a new investment topic each week. In this first edition, host Dr Nigel Finch examines the coronavirus-induced boom of the telehealth industry. Populatin...

Maternity telehealth company HeraMED (ASX: HMD) revealed this morning in a conference call it was in “advanced discussions” regarding the expedited commercial roll-out of its platform across the US, UK, Australia and Israel. The company’s H...

HeraMED Limited (ASX:HMD), a medical technology company leading the digital transformation of maternity care with its proprietary in-home maternity care platform, advised on Tuesday morning that it had received a significant uplift in inter...